Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: mlkr who wrote (3025)	7/13/2010 1:46:04 PM
From: mlkr	Respond to of 3722

TBRN was $20 in 2007 with WYETH's back up which was bought by PFE: BY JONATHAN D. ROCKOFF AND PETER LOFTUS Pfizer Inc. is developing improved versions of top-selling biotechnology drugs, becoming the latest big drug maker to take aim at the biotech industry. Among its projects are three large molecules now in mid-stage development, according to Pfizer officials. Two of them aim to improve on Rituxan, a treatment for certain blood cancers and rheumatoid arthritis that is co-marketed by Roche Holding AG and Biogen Idec Inc. The third seeks to reduce how often medicines like Enbrel, a rheumatoid arthritis medicine that Pfizer co-markets with Amgen Inc., need to be injected. Pfizer bought Wyeth for $68 billion last year partly to ..

To: mlkr who wrote (3025)	7/13/2010 7:39:28 PM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

TRBN seems to have found support at the $2.35 level. Today it was just closing yesterday's little UG before trying the resistance at the $3 level<g> bigcharts.marketwatch.com I mentioned that PFE had decided to discontinue development of PF-05212374, one of the two investigational R.A. drugs on which the companies are collaborating. But the other TRBN's drug candidate for R.A., SBI-087 will still continue on its PII as PFE's PF-05230895 and the companies are still evaluating SRI-087 as a possible treatment for S.L.E. TRBN also has some other drugs in its pipeline. Message 26677780 The stock remains speculative, but I still will keep my T.T. at the $5 level.<g> Bernard